NPLEx gaining strength in battle against meth
More and more, the diversion of nonprescription pseudoephedrine is being halted at the pharmacy counter in real time thanks to tools like the National Precursor Log Exchange, funded entirely by the industry and now active in 17 states.
NPLEx is already operational in most of the states with the greatest number of operational meth labs — 78% of meth lab incidents in 2010 were concentrated across 11 states stretching from Alabama to Michigan, according to an El Paso Intelligence Center National Seizure System survey published in August. And NPLEx is active in all but three of those states. In all states where NPLEx is operational, 47,866 PSE sales were blocked each month over first quarter 2011, representing 4.1% of all sales. In non-NPLEx states over that quarter, 19,535 sales were blocked, representing 1.4% of sales, according to a Consumer Healthcare Products Association document.
In the past year, as many as 16 states have been considering more radical legislation — mandating that common cough-cold products containing PSE be available only by prescription. It’s a move that significantly hampers legitimate consumer access to cough-cold relief and at the same time increases healthcare costs by requiring a doctor’s visit for the common cold, argued the CHPA. According to the CHPA, as many as 100 bills concerning the sale of PSE products have been filed across 24 states and 12 localities — including 26 bills to install electronic tracking mandates and 43 bills to re-classify PSE as prescription-only.
The Virginia State Crime Commission last month identified four states where Rx-only laws are still under consideration: Alabama, Nevada, Oklahoma and Tennessee. All together, 19 states have electronic tracking mandates. An NPLEx bill in Georgia will be revisited in 2012.
Rx-only legislation will likely return for debate in 2012 in four states: California, Hawaii, Kentucky and Oklahoma. In Michigan and Tennessee, Rx-only legislation currently stands before committees. In the remaining states where Rx-only legislation had been considered this year, that legislation is no longer active.
Scorpiniti to take top spot at Katz Group
MISSISSAUGA, Ontario — The retirement of Katz Group Canada CEO Andy Giancamilli come February will mark the rise of pharmacy veteran Frank Scorpiniti, who will take the helm of the Canadian retailer.
Scorpiniti joined Katz Group Canada in April 2011 as COO. Long regarded as one of the bright young executives in retail pharmacy, Scorpiniti now will get a chance to lead a progressive Canadian pharmacy chain, with a hot new Rexall Healthy Living concept, a national presence under Rexall and a slew of innovative programs like the employer-based Rexall Network program.
“We brought Frank on board in April of this year, and he’ll take over Feb. 1, which is almost a year transition. We got to know him and feel very comfortable with his leadership style. So we are leaving the company in good hands, and it is a strong company,” Giancamilli told Drug Store News. “You know when it’s the right time, and it’s the right time.”
With more than 20 years of retail pharmacy experience, Scorpiniti previously served as SVP pharmacy operations at Duane Reade, a post he held since December 2008. At Duane Reade, the efforts on the back end in pharmacy, spearheaded by Scorpiniti and his team, resulted in a cost reduction for the company, better in-stocks for stores and less wait time for pharmacy customers.
Scorpiniti came to Duane Reade from West Coast regional player Longs Drug Stores, which was acquired by CVS Caremark in October 2008. While at Longs, Scorpiniti held positions of increasing responsibility and ultimately served as VP pharmacy operations, overseeing all aspects of Longs’ pharmacy business.
Now Scorpiniti inherits Katz Group, which encompasses more than 1,800 chain, franchise and independent pharmacies across Canada.
Lupin launches contraceptive authorized generic
NEW YORK — Indian generic drug maker Lupin has launched an authorized generic version of a birth control pill made by Warner Chilcott, according to published reports.
Dow Jones reported that Lupin launched an authorized generic of Femcon (norethindrone and ethinyl estradiol tablets, ferrous fumarate tablets).
An authorized generic is a branded drug sold under its generic name at a reduced price, usually through a third-party company.